Post-COVID-19 Condition Treatment
- Epidemiological study to uncover the facts about post-COVID-19 condition
- Clinical study to examine if antiviral treatment can reduce the risk of post-COVID-19 condition
Joint research program to work on the elucidation of the pathology of post-COVID-19 condition (aftereffects) that still remain as social challenges
Some patients recovered from the acute phase of COVID-19 report various aftereffects such as respiratory conditions, cardiovascular conditions, taste/smell disorders, and nerve disorders, which are causing concerns about decline of QOL and impact on social life.
Many of the pathological mechanisms behind these conditions are still unknown, with no established treatment and prevention methods.
In recent years, multiple reports have suggested that antiviral treatment during the acute phase may reduce aftereffects; however, this remains to be demonstrated in prospective studies.
Shionogi & Co., Ltd. has developed ensitrelvir fumarate, a new oral antiviral drug to inhibit 3C-like protease required for the proliferation of SARS-CoV-2, which has been approved in Japan and widely used as a treatment for COVID-19.
We will conduct a prospective study to examine if treatment with ensitrelvir during the acute phase of COVID-19 reduces the risk of aftereffects.
The goal of this joint research program is to use ensitrelvir as well as other drugs and vaccines that have the potential to solve social challenges to elucidate the pathology of aftereffects and establish the treatment and prevention methods in industry-academia collaboration.
